shortage of glp-1 receptor agonists Metabolic Consequences Glucagon-Like Peptide-1 Agonist Shortage: Deterioration of Glycemic Control in Type 2 Diabetes GLP-1 Receptor Agonist Shortage: Challenges

[DOI] [PMC free article] [PubMed] [Google Scholar] 757.McKay N.J., Galante D.L., Daniels D

[24] [25] These laboratory findings suggest potential protective mechanisms, though their clinical relevance in humans remains uncertain

Also, a recent systematic review indicates that tirzepatide treatment in adults is associated with reductions in fat mass, relative preservation of lean mass, and decreases in MFI [69], all of which are critical for sarcopenia risk and functional capacity

While mild to moderate nausea is expected with GLP-1 therapy, certain symptoms warrant prompt medical evaluation

Diabetes Care 2020

doi: 10.1016/S0167-0115(02)00157-X [DOI] [PubMed] [Google Scholar] 31.Bodnaruc AM, Prudhomme D, Blanchet R, et al